JAZZ
Jazz PharmaceuticalsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
JAZZ Profile
Jazz Pharmaceuticals Public Limited Company
A company that developing drugs in the therapeutic areas of narcolepsy, oncology, pain, and psychiatry
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7
--
Jazz Pharmaceuticals Public Limited Company is a public limited liability company established in March 2005 under the laws of Ireland. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on the identification, development and commercialization of pharmaceutical products to meet huge medical needs.
Since its establishment in 2003, it has established a commercial and development organization, and the assembled products and product candidates currently include two products on sale, as well as product candidates that are in various stages of clinical development. It currently sells two products: Xyrem (sodium oxybate), the only product approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy due to drowsiness and excessive daytime sleepiness; and blue-release CR (fluvoxamine maleate) for the treatment of obsessive-compulsive disorder. The Company promotes sales of these products in the United States through its experienced professional sales force of sleep specialists, neurologists, pulmonologists and psychiatrists.
